Pharmacodynamic-Tolerability Relationships of Cholinesterase Inhibitors for Alzheimer??s Disease

This publication has 85 references indexed in Scilit:

• Structure of acetylcholinesterase complexed with (−)‐galanthamine at 2.3 Å resolution
  FEBS Letters, 1999
• Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease
  Drug Safety, 1998
• Steady-State Pharmacokinetics of Tacrine in Long-Term Treatment of Alzheimer Patients
  Dementia and Geriatric Cognitive Disorders, 1996
• Clinical Pharmacokinetics of Tacrine
  Clinical Pharmacokinetics, 1995
• Relationship Between Pharmacokinetics and Pharmacodynamics of Eptastigmine in Young Healthy Volunteers
  The Journal of Clinical Pharmacology, 1995
• Muscarinic receptors mediate attenuation of extracellular acetylcholine levels in rat cerebral cortex after cholinesterase inhibition
  Neuroscience Letters, 1993
• Inhibition of Acetylcholinesterase Activity in Human Brain Tissue and Erythrocytes by Galanthamine, Physostigmine and Tacrine
  cclm, 1991
• Carbamate analogues of (−)‐physostigmine: In vitro inhibition of acetyl‐ and butyrylcholinesterase
  FEBS Letters, 1988
• Inhibition of acetylcholinesterase from electric eel by (−)‐ and (+)‐physostigmine and related compounds
  FEBS Letters, 1986
• Clinical diagnosis of Alzheimer's disease
  Neurology, 1984